Fibrolamellar Carcinoma — Trials

Fibrolamellar Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

21 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 11
Recruiting: 8
Ph III recruiting: 0
Growth YoY: —
Industry share: 18%
Top sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (4)

clinicaltrialsPublishedShowing 1–6 of 6 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT04380545	Nivolumab, Fluorouracil, and Interferon Alpha 2B for the Treatment of Unresectable Fibrolamellar Cancer	recruiting	Phase 1 / Phase 2	15	M.D. Anderson Cancer CenterOTHER	1	Sep 14, 2026	clinicaltrials
NCT05468359	Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients	recruiting	Phase 1 / Phase 2	64	St. Jude Children's Research HospitalOTHER	1	May 19, 2026	clinicaltrials